HilleVax, Inc. (NASDAQ:HLVX) Given Average Recommendation of "Hold" by Brokerages

HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) has been given a consensus rating of "Hold" by the six ratings firms that are covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold rating. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $3.00.

Separately, HC Wainwright restated a "neutral" rating and issued a $2.00 price target on shares of HilleVax in a report on Monday, March 31st.

HilleVax Stock Down 3.6%

NASDAQ HLVX traded down $0.07 on Friday, reaching $1.85. The company had a trading volume of 354,921 shares, compared to its average volume of 447,845. The stock's 50 day moving average is $1.85 and its 200-day moving average is $1.85. The stock has a market cap of $92.76 million, a price-to-earnings ratio of -0.60 and a beta of 0.74. HilleVax has a 52 week low of $1.34 and a 52 week high of $15.60.

HilleVax (NASDAQ:HLVX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.25. As a group, analysts forecast that HilleVax will post -2.64 EPS for the current year.

Institutional Investors Weigh In On HilleVax

Several large investors have recently modified their holdings of HLVX. Takeda Pharmaceutical Co. Ltd. acquired a new position in shares of HilleVax during the fourth quarter worth about $13,919,000. Lightspeed Management Company L.L.C. acquired a new position in shares of HilleVax during the fourth quarter worth about $4,847,000. Trium Capital LLP acquired a new position in shares of HilleVax during the first quarter worth about $548,000. JPMorgan Chase & Co. boosted its position in shares of HilleVax by 1,376.8% during the fourth quarter. JPMorgan Chase & Co. now owns 207,151 shares of the company's stock worth $429,000 after buying an additional 193,124 shares during the period. Finally, Millennium Management LLC boosted its position in shares of HilleVax by 59.6% during the fourth quarter. Millennium Management LLC now owns 411,820 shares of the company's stock worth $852,000 after buying an additional 153,815 shares during the period. 86.42% of the stock is currently owned by institutional investors.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.